ESMO 2018 Congress: Highlights in HR-positive, HER2-negative advanced breast cancer LBA2_PR

Dr. Massimo Cristofanilli reports on key results from ESMO 2018 Congress: LBA2_PR: Overall survival with palbociclib plus fulvestrant in women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Analyses from PALOMA-3. Produced by the European Society for Medical Oncology